Analysts forecast that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will announce sales of $26.70 million for the current quarter, Zacks reports. Five analysts have provided estimates for Arcturus Therapeutics' earnings. The highest sales estimate is $73.02 million and the lowest is $1.80 million. Arcturus Therapeutics reported sales of $2.33 million during the same quarter last year, which would suggest a positive year over year growth rate of 1,045.9%. The firm is expected to report its next earnings results on Monday, November 8th.
On average, analysts expect that Arcturus Therapeutics will report full year sales of $91.01 million for the current fiscal year, with estimates ranging from $6.60 million to $277.12 million. For the next fiscal year, analysts anticipate that the firm will report sales of $465.18 million, with estimates ranging from $6.00 million to $965.90 million. Zacks' sales averages are a mean average based on a survey of sell-side analysts that cover Arcturus Therapeutics.
Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Sunday, August 8th. The biotechnology company reported ($2.07) EPS for the quarter, missing analysts' consensus estimates of ($1.99) by ($0.08). Arcturus Therapeutics had a negative return on equity of 48.39% and a negative net margin of 1,874.18%.
Several brokerages have weighed in on ARCT. Zacks Investment Research raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, August 10th. Cantor Fitzgerald lifted their price target on shares of Arcturus Therapeutics from $71.00 to $85.00 and gave the company an "overweight" rating in a report on Tuesday, August 10th. Citigroup lowered their price target on shares of Arcturus Therapeutics from $118.00 to $114.00 and set a "buy" rating on the stock in a report on Wednesday, August 25th. Raymond James downgraded shares of Arcturus Therapeutics from a "market perform" rating to an "underperform" rating in a report on Thursday, August 12th. Finally, The Goldman Sachs Group downgraded shares of Arcturus Therapeutics from a "neutral" rating to a "sell" rating and set a $29.00 price target on the stock. in a report on Tuesday, August 10th. Six analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $69.33.
In related news, COO Pad Chivukula sold 10,000 shares of the business's stock in a transaction on Tuesday, August 3rd. The shares were sold at an average price of $40.07, for a total value of $400,700.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ultragenyx Pharmaceutical Inc. sold 725,000 shares of the business's stock in a transaction on Tuesday, August 10th. The shares were sold at an average price of $55.44, for a total transaction of $40,194,000.00. Following the transaction, the director now owns 1,475,000 shares in the company, valued at approximately $81,774,000. The disclosure for this sale can be found here. Insiders sold 745,000 shares of company stock worth $41,153,300 in the last 90 days. 12.20% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC bought a new position in shares of Arcturus Therapeutics in the first quarter worth about $356,000. UBS Group AG grew its holdings in shares of Arcturus Therapeutics by 52.2% in the first quarter. UBS Group AG now owns 42,810 shares of the biotechnology company's stock worth $1,768,000 after purchasing an additional 14,682 shares during the last quarter. We Are One Seven LLC grew its holdings in shares of Arcturus Therapeutics by 12.0% in the second quarter. We Are One Seven LLC now owns 30,216 shares of the biotechnology company's stock worth $1,023,000 after purchasing an additional 3,226 shares during the last quarter. UBS Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics by 11.1% in the first quarter. UBS Asset Management Americas Inc. now owns 16,225 shares of the biotechnology company's stock worth $670,000 after purchasing an additional 1,625 shares during the last quarter. Finally, Rafferty Asset Management LLC grew its holdings in shares of Arcturus Therapeutics by 177.4% in the second quarter. Rafferty Asset Management LLC now owns 186,829 shares of the biotechnology company's stock worth $6,322,000 after purchasing an additional 119,483 shares during the last quarter. Hedge funds and other institutional investors own 77.64% of the company's stock.
Shares of NASDAQ ARCT opened at $52.29 on Thursday. The firm has a 50 day moving average of $44.47 and a 200 day moving average of $39.63. The company has a current ratio of 8.81, a quick ratio of 8.81 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -8.18 and a beta of 2.91. Arcturus Therapeutics has a 12-month low of $24.87 and a 12-month high of $129.71.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Recommended Story: What are momentum indicators and what do they show?
Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here